A new antibiotic produced by bacteria found on a species of African ant, is very potent against antibiotic-resistant superbugs like MRSA according to scientists. Researchers at the University of East Anglia (UEA) and the John Innes Centre (JIC) discovered a new member of the Streptomyces bacteria family, isolated from the African fungus-growing plant-ant Tetraponera penzigi. They have named the new species Streptomyces formicae and the antibiotics formicamycins, after the Latin formica, meaning ant.
Lab tests have shown these new antibiotics are effective against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE), bacteria which are resistant to a number of common antibiotics and can cause life-threatening infections.
Almost all of the antibiotics currently in clinical use come from a group of bacteria called actinomycetes that were isolated from soil between 40-80 years ago, the 'golden age' of antibiotic discovery. Inappropriate use of these antibiotics since then has led to widespread antimicrobial resistance (AMR), where disease-causing bacteria and fungi have become resistant to one or more antibiotics.
Professor Matt Hutchings from UEA said, "We have been exploring the chemical ecology of protective symbioses formed between antibiotic-producing bacteria and fungus-growing insects to better understand how these associations are formed and explore them as a new source of anti-infective drugs.
"Kenyan plant-ants live in symbiosis with thorny acacia trees. They live and breed in domatia -- which are hollowed out structures which the plant evolved to house them - and grow fungus in them for food. In return, they protect the plants from large herbivores including elephants, which won't eat plants covered in ants."
The team isolated a number of actinomycete bacterial strains from the acacia plant housing the ants, selecting a number for genome sequencing. One particular strain caught their attention, and the antibiotic compounds produced from it showed promising activity in early tests against other disease-causing bacteria.
Hutchings said, "We tested formicamycins against clinical isolates of MRSA and VRE and found that they are very potent inhibitors of these organisms."
To test this further, they repeated the tests by growing the strains for 20 generations in very low, sub-inhibitory concentrations of formicamycins and found no sign that the test strains acquired spontaneous higher level resistance to the new antibiotics.
Wilkinson from JIC said, "Our findings highlight the importance of searching as-yet under-explored environments, which, when combined with recent advances in genome sequencing and editing, enables the discovery of new species making natural product antibiotics which could prove invaluable in the fight against AMR."
'Formicamycins, antibacterial polyketides produced by Streptimyces formicae isolated from African Tetreponera plant-ants' is published in the journal Chemical Science.
Source: University of East Anglia
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.